NeuroDerm Ltd. (NDRM) Trading Up 3.6%
NeuroDerm Ltd. (NASDAQ:NDRM) shares were up 3.6% during trading on Thursday . The company traded as high as $18.64 and last traded at $18.51, with a volume of 76,731 shares. The stock had previously closed at $17.86.
A number of research analysts have commented on NDRM shares. Oppenheimer Holdings Inc. reaffirmed an “outperform” rating and set a $24.00 target price on shares of NeuroDerm in a report on Friday, April 1st. Roth Capital reaffirmed a “buy” rating on shares of NeuroDerm in a report on Sunday, May 29th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $24.70.
The stock has a 50 day moving average of $16.91 and a 200 day moving average of $15.43. The company’s market cap is $406.47 million.
NeuroDerm (NASDAQ:NDRM) last released its earnings results on Thursday, May 26th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.35) by $0.10. On average, analysts forecast that NeuroDerm Ltd. will post ($1.52) earnings per share for the current year.
NeuroDerm Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in developing treatments for central nervous system (CNS) disorders, primarily Parkinson’s disease, as well as other CNS diseases. The Company is developing ND0612H for the treatment of patients suffering from severe Parkinson’s disease; ND0612L for the treatment of patients at the moderate stage of Parkinson’s disease that can no longer control motor complications with oral levodopa, and ND0680 for the treatment of a small subset of severe Parkinson’s disease patients, whose symptoms have advanced to a severe stage, requiring even higher doses of LD/CD than ND0612H is designed to provide.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.